![]() ![]() It does not store any personal data.You would believe so if you observe VCs. The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. The cookie is used to store the user consent for the cookies in the category "Performance". This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. The cookies is used to store the user consent for the cookies in the category "Necessary". The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". The cookie is used to store the user consent for the cookies in the category "Analytics". These cookies ensure basic functionalities and security features of the website, anonymously. Necessary cookies are absolutely essential for the website to function properly. He is also a former member of the board of directors of listed companies, including Prevas, Skanditek, Alligator Bioscience, Amersham, Novozymes, Bure and Biotage. He was the President of the European Federation of Biotechnology between 20. Professor Mathias Uhlén is a member of the Royal Swedish Academy of Engineering Science, IVA, the Royal Swedish Academy of Science, KVA, the European Molecular Biology Organization, EMBO, and a member of the National Academy of Engineering (USA). “Through these joint efforts using our technologies, we have a unique possibility to play a crucial role in the commercialisation of large-scale screenings and personalised medicine diagnostics,” says Christopher Aulin. The work is based on Capitainer’s products and analysis using proteomics assays developed by research and infrastructure groups at the Department of Protein Science, KTH. Capitainer’s products, delivering high precision accuracy blood and plasma sampling, are the missing link to enable a broader implementation of personalised medicine, proteomics, and clinical monitoring in today’s healthcare, says Mathias Uhlén.Īlready in collaboration with Mathias Uhlén and researchers at SciLifeLab, Capitainer is developing new specialised solutions for personalised medicine. “I am thrilled to be part of the Capitainer advisory board, and I see great potential in the technologies Capitainer provides. He has founded 20 companies and has more than 70 international patent applications. His work has been translated by several companies ranging from early start-ups to large international companies, developing industrial applications of his research. Mathias Uhlén’s research has led to over 750 publications in scientific journals. His grit, knowledge, and experience of breaking new ground is an invaluable asset for Capitainer as we are taking a leap into the world of proteomics assays,” says Christopher Aulin, CEO of Capitainer. “We are more than delighted to have Mathias Uhlén on board. Mathias Uhlén’s research interests cover antibody engineering, proteomics, and precision medicine. He was also the Founding Director of the Science for Life Laboratory, SciLifeLab, 2010–2015. Mathias Uhlén is a biotechnologist, entrepreneur, and Professor of Microbiology at the KTH Royal Institute of Technology in Stockholm and is widely known for his work in large-scale quantitative analysis of proteins and leadership of the Human Protein Atlas project. The precision and accuracy in Capitainer’s samples are market-leading and perform on the same level as established pipetting methods. The sample card can be sent with regular mail to laboratories with no need for refrigerated transports or special packaging. The startup has developed a unique technology for collecting an exact amount of fluid and then allowing it to dry. It develops and sells intelligent solutions for self-sampling blood, plasma, and urine. Patients can themselves conveniently leave blood samples (as dried blood spots) and send them by mail to a laboratory for analysis.Ĭapitainer AB was founded in 2016. The startup develops a microsystem-based technology that offers a solution for near-patient blood sampling e.g. The well-renowned scientist will be joining the advisory board of the company. Swedish Professor Mathias Uhlén is investing in Stockholm-based medtech startup Capitainer. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |